澳股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

RECCE PHARMACEUTICALS LTD

0.265

-0.025-8.62%

成交量：14.71万

成交额：4.07万

市值：8,096.28万

市盈率：-5.13

高：0.285

开：0.285

低：0.265

收：0.290

52周最高：0.730

52周最低：0.265

股本：3.06亿

流通股本：1.69亿

量比：1.01

换手率：0.09%

股息：- -

股息率：- -

每股收益(TTM):-0.052

每股收益(LYR):-0.052

净资产收益率：-1277.62%

总资产收益率：-82.75%

市净率：-4.84

市盈率(LYR):-5.13

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Recce Pharmaceuticals Ltd 研发新型合成抗感染药物直击耐药超级细菌

Recce Pharmaceuticals称HREC批准加速其全球III期DFI战略

Recce Pharmaceuticals Ltd 获许可方于沙特、海合会、埃及、阿尔及利亚及摩洛哥获得R327g独家权利

Recce Pharmaceuticals Ltd 将获净售价30%分成及超5000万美元年销售额6%特许权使用费

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hans/stock/RCE.AU"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","market":"AU","secType":"STK","nameCN":"RECCE PHARMACEUTICALS LTD","latestPrice":0.265,"timestamp":1791868320000,"preClose":0.29,"halted":0,"volume":147062,"delay":0,"changeRate":-0.08620689655172403,"nameEN":"RECCE PHARMACEUTICALS LTD","floatShares":168893037,"shares":305520100,"eps":-0.0517,"marketStatus":"已收盘","change":-0.025,"latestTime":"10-13 16:12:00 AEDT","open":0.285,"high":0.285,"low":0.265,"amount":40736,"amplitude":0.068966,"askPrice":0.27,"askSize":9436,"bidPrice":0.265,"bidSize":19999,"shortable":3,"etf":0,"ttmEps":-0.0517,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":0,"beginTime":1791932400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.29,"openAndCloseTimeList":[[1791846000000,1791867600000]],"volumeRatio":1.013287,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RCE.AU","preClose":0.29,"auctionPrice":0.265,"auctionVolume":25000,"auctionTime":1791868122674,"referencePrice":0.265,"referenceTime":1791878400906,"auction":3,"marketStatus":"盘后竞价","timestamp":1791868122674}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","floatShares":168893037,"roa":"-82.75%","roe":"-1277.62%","lyrEps":-0.0517,"volumeRatio":1.013287,"shares":305520100,"dividePrice":0,"high":0.285,"amplitude":0.068966,"preClose":0.29,"low":0.265,"week52Low":0.265,"pbRate":"-4.84","psRate":"8.55","week52High":0.73,"institutionHeld":0,"latestPrice":0.265,"committee":0.358859,"eps":-0.0517,"divideRate":0,"volume":147062,"delay":0,"ttmEps":-0.0517,"open":0.285,"prevYearClose":0.65,"prevWeekClose":0.295,"prevMonthClose":0.315,"prevQuarterClose":0.315,"fiveDayClose":0.315,"twentyDayClose":0.32,"sixtyDayClose":0.37,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCE.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-04-15","symbol":"RCE.AU","defaultRemindTime":1744675200000,"type":"split","dateTimestamp":1744639200000,"forFactor":990476,"toFactor":1000000,"ratio":0.990476}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCE.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCE.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1195921803","title":"Recce Pharmaceuticals Ltd 研发新型合成抗感染药物 直击耐药超级细菌","url":"https://stock-news.laohu8.com/highlight/detail?id=1195921803","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195921803?lang=zh_cn&edition=fundamental","pubTime":"2026-07-30 08:40","pubTimestamp":1785372009,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd（简称RCE）正致力于开发一种全新类型的合成抗感染药物。这些药物旨在应对那些对现有抗生素产生耐药性的超级细菌，直击当前全球公共卫生领域的重大威胁。通过设计独特的合成分子，该公司力求在耐药性问题上实现突破，为日趋严峻的感染治疗困境提供新方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110230784","title":"Recce Pharmaceuticals称HREC批准加速其全球III期DFI战略","url":"https://stock-news.laohu8.com/highlight/detail?id=1110230784","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110230784?lang=zh_cn&edition=fundamental","pubTime":"2026-06-22 09:35","pubTimestamp":1782092148,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd宣布，其人类研究伦理委员会的批准将加速公司在全球范围内实施针对糖尿病足感染的III期临床试验战略。这一进展标志着公司在该关键治疗领域迈出了重要一步。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139423312","title":"Recce Pharmaceuticals Ltd 获许可方于沙特、海合会、埃及、阿尔及利亚及摩洛哥获得R327g独家权利","url":"https://stock-news.laohu8.com/highlight/detail?id=1139423312","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139423312?lang=zh_cn&edition=fundamental","pubTime":"2026-05-27 07:51","pubTimestamp":1779839482,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd 宣布，其许可合作方已获得在沙特阿拉伯、海湾合作委员会国家、埃及、阿尔及利亚及摩洛哥市场开发与商业化新型抗菌候选药物R327g的独家权利。此项授权协议的达成，标志着该公司在中东与北非关键市场的战略布局取得重要进展，有望进一步拓展其核心产品的全球覆盖范围。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198655607","title":"Recce Pharmaceuticals Ltd 将获净售价30%分成及超5000万美元年销售额6%特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1198655607","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198655607?lang=zh_cn&edition=fundamental","pubTime":"2026-05-27 07:51","pubTimestamp":1779839475,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals Ltd 已达成一项关键商业协议。根据协议条款，该公司将有权获得其产品销售净售价的30%作为分成。此外，当年销售额超过5000万美元时，Recce还将额外获得超出部分销售额6%的特许权使用费。这一安排为该公司未来的收入流奠定了重要基础，并与其核心产品的商业化前景紧密相连。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RCE.AU\",params:#limit:6,delay:true,,,undefined,":[]}}